Sunesis Pharmaceuticals Inc. launched its Phase III trial of vosaroxin in combination with cytarabine in relapsed and refractory acute myeloid leukemia. The drug showed encouraging results from its Phase II studies, including excellent safety and tolerability in its sensitive elderly patient population.